Title

Unpredictability in Patent Law and its Effect on Pharmaceutical Innovation

Publication Date

2011

Document Type

Article

Abstract

In recent years, the major innovator pharmaceutical companies have experienced two pronounced and significant trends: a decreasing output of innovative new drugs and cutbacks in research and development (R&D) investment. The two phenomena probably are not unrelated and raise significant concerns for a society intent upon providing affordable health care for an aging population. While the root causes of these trends are complex and diverse, we should not overlook the critical role patents play in creating the necessary incentives for the substantial investment required to develop pharmaceutically-interesting chemical compounds into actual drugs and to take them through the clinical trials necessary for Food and Drug Administration (FDA) approval. In a recent presentation, Robert Armitage, Senior Vice President and General Counsel for Eli Lilly and Co. (Lilly), identified the high level of unpredictability in today's patent law as a significant impediment to the development of new medicines. This Article discusses various forms of unpredictability in patent law and how they impact innovators, particularly in the pharmaceutical sector, and provides some ideas for addressing the problem.

Publication Title

Missouri Law Review

Volume

76

Issue

3

Share

COinS